Jeremy P. Carver, Ph.D., Chair of the Board of Directors
Dr. Carver is an experienced biotechnology entrepreneur; Besides his role at Nashoba Biotechnology, he is currently the Co-Founder, President and CEO of the International Consortium on Anti-Virals (ICAV-CITAV), an organization of over 500 scientists from 38 countries dedicated to discovering and delivering low-cost anti-viral drugs to low and middle income countries. Dr. Carver co-founded ICAV, with offices near Montreal, with Dr. Michel Chrétien in June 2004. Previously, Dr Carver was the Founding President, CEO and CSO of GlycoDesign Inc (1994 -2002), a biotech company listed on the TSE in 2000 and which received the Friesen-Rygiel Award in 2001.
He is an Emeritus Professor at the University of Toronto; an Honorary Conjunct Professor at Trent University; and, an Adjunct Professor at York University in Toronto. He was a Professor (1968-94) and Associate Dean Basic Science (1989-1992), Faculty of Medicine, University of Toronto. As Associate Dean he was central to the creation of a critical mass in Structural Biology in the Faculty of Medicine.
Dr. Carver received a Ph.D. (Biophysics, Harvard University) and an Hons. B.A. (Physics, University of Toronto), a Helen Hay Whitney Postdoctoral Fellowship (Oxford University) and a World Trade Visiting Scientist Award (IBM Watson Labs). His research specialties include biotechnology, glycobiology, company creation, and drug development.